14th Feb, 2019, Bioheng announced the completion of a 100 million RMB serial A financing, which was exclusively invested by Decheng Capital. With this support, Bioheng will engage in talent recruiting, GMP facilities construction as well as the development and commercialization of “off the shelf” universal immunotherapy products.
Dr. Cui, founder and chairman of Decheng Capital, said: “We are very optimistic about the future of universal CAR-T and its great potential in curing cancers. We are highly impressed by the scientific background, pre-clinical data, product pipeline, and the entrepreneur spirit of Bioheng. We are very pleased to reach an in-depth cooperation with Bioheng, and believe Bioheng could grow to an outstanding company with our joint efforts.”
Dr. He, founder and CEO of Bioheng mentioned that "We are honored to collaborate with Decheng Capital, a well-known investment institute in the field of biotech and pharmaceuticals. We appreciate Decheng Capital for its resonance with our mission, value and management model. Bioheng has raised more than 100 million RMB within one year. Thanks for the recognitions of all parties, we will continue to strengthen our research and trials in immunotherapy, and this will undoubtedly greatly boost the process of our products development and clinical applications.
Copyright Nanjing Bioheng Biotech Co., Ltd.@ 2018 China All Rights Reserved